VYNE (VYNE Therapeutics) Float Percentage Of Total Shares Outstanding: 98.61% (As of Jul. 09, 2026)


VYNE VYNE Therapeutics Inc VYNE
37 GF Score
Price $0.66
GF Value $0.56
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is VYNE Therapeutics Float Percentage Of Total Shares Outstanding?

VYNE Therapeutics VYNE -2.88% 37 Float Percentage Of Total Shares Outstanding is 98.61% as of Jul. 09, 2026. GuruFocus rates VYNE with a GF Score™ of 37/100 and a GF Value™ of $0.56 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, VYNE Therapeutics's float shares is 32.93 Mil. VYNE Therapeutics's total shares outstanding is 33.39 Mil. VYNE Therapeutics's float percentage of total shares outstanding is 98.61%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, VYNE Therapeutics's Insider Ownership is 6.62%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, VYNE Therapeutics's Institutional Ownership is 44.28%.

VYNE
37GF Score
VYNE Therapeutics Inc VYNE
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VYNE Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

VYNE Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=32.93/33.39
=98.61%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 98.61% mean?
VYNE Therapeutics (VYNE) has a Float Percentage Of Total Shares Outstanding of 98.61% as of Jul. 09, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on VYNE Therapeutics and its competitors.
Is VYNE Therapeutics' Float Percentage Of Total Shares Outstanding too high?
VYNE Therapeutics' current Float Percentage Of Total Shares Outstanding is 98.61%. Overall, VYNE Therapeutics has a GF Score™ of 37/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does VYNE Therapeutics' Float Percentage Of Total Shares Outstanding compare to PLUR and MRKR?
VYNE Therapeutics' Float Percentage Of Total Shares Outstanding of 98.61% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on VYNE Therapeutics and its competitors. VYNE Therapeutics's current Float Percentage Of Total Shares Outstanding is 98.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VYNE Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, VYNE Therapeutics (VYNE) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.56, compared to a current price of $0.66 — trading 18.6% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 98.61%. VYNE Therapeutics' overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For VYNE Therapeutics (VYNE), the current Float Percentage Of Total Shares Outstanding is 98.61% as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is VYNE Therapeutics (VYNE) Overvalued in 2026?

Based on GuruFocus' analysis, VYNE Therapeutics stock appears to be overvalued. The current stock price of $0.66 is trading 18.6% above its estimated GF Value™ of $0.56. GuruFocus considers VYNE Therapeutics to be Modestly Overvalued.

Key valuation signals for VYNE:

  • Float Percentage Of Total Shares Outstanding: 98.61%
  • GF Value™: $0.56 vs. price of $0.66 (18.6% above fair value)
  • GF Score™: 37/100 with 5 warning signs

No single metric tells the full story. See the VYNE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

VYNE Therapeutics Business Description

Address P.O. Box 125, Stewartsville, NJ, USA, 08886
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
37GF Score

Get the complete analysis for VYNE

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.66
Price
$0.56
GF Value